摘要
用乳腺癌术后腋下淋巴结淋巴细胞与人鼠骨髓瘤细胞ＳＨＭ－Ｄ_（３３）融合，获得分泌抗乳腺癌人单克隆抗体杂交瘤细胞株ＣＭ－１。用ＰＡＰ免疫组化法分析，ＣＭ－１与被检乳腺癌均呈阳性反应，但与乳腺纤维瘤和被检其他肿瘤组织及正常组织均无反应。ＣＭ－１用于裸鼠移植瘤放免显像（ＲＩＩ）能进行肿瘤定位。ＲＩＩ对乳腺癌志愿者能初步达到乳腺癌腋下淋巴结转移灶定位。ＣＭ－１－药物（平阳霉素；ＰＹＭ）偶联物对裸鼠移植乳腺癌生长的抑瘤率为９５％，而同等剂量的游离药物为５８％。显示了抗乳腺癌人单抗ＣＭ－１的特异性及其在临床诊断和治疗乳腺癌中的光明前景。
With fusion of human heteromyeloma cells SHM-D_(33)and B lymphcytes obtained from axillary lymph nodes of a patient suffering from breast carcinoma,one hybridoma cell line which secretes human monoclonal antibody CM-1 to breast carcinoma was established.The hybridoma cells have been secreting human IgM(λlight chain)stably for over 5 years.The CM-1 concentration of the supernatant of cell culture is 38.5μg per ml and is the ascites that of 2 mg per ml.The reactivity of CM-1 to normal human tissues and several kinds of tumors was examined with immunohistochemical staining.The results showed that the CM-1 reacted strongly to breast carcinoma and weakly to myxoadenocarcinoma of the esophagus.CM-1did not react to normal tissues or other kinds of tumors,such as breast fibroadenoma,medullary carcinoma of the thyroid,etc,After injection of￣(131)I-CM-1 into abdominal cavity of the mice bearing breast carcinoma,the image of xenografted carcinoma can be obviously distinguished from the background of normal tissuss.The inhibitory effect on growth of breast cancer xenograft in nude mice was 95% for CM-1-PYM conjugate and 58%for free drug.The above results showed that the hybridom cell line CM-1 stably secreting antibody reacted specificaly with breast carcinoma and it might be useful as a drug carrier in therapy of patients with breast carcinoma.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
1996年第3期177-182,共6页
Acta Academiae Medicinae Sinicae
基金
国家"863"项目基金
